alpha-(苄基硫代)乙酰胺 | 54744-70-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: alpha-(苄基硫代)乙酰胺
• 英文名称: 2-benzylsulfanyl-acetamide
• 英文别名: benzylsulfanyl-acetic acid amide；Benzylmercapto-essigsaeure-amid；C-Benzylmercapto-acetamid；S-Benzyl-thioglykolsaeure-amid；2-(benzylthio)acetamide；(Benzylthio)essigsaeureamid；Acetamide, 2-(benzylthio)-；2-benzylsulfanylacetamide
• CAS: 54744-70-6
• 化学式: C₉H₁₁NOS
• mdl: MFCD00025525
• 分子量: 181.258
• InChiKey: SSAAMOPNNPAZDB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  68.4
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2930909090

反应信息

• 作为反应物：
  描述：

  alpha-(苄基硫代)乙酰胺 在 tetraphosphorus decasulfide 、 potassium sulfide 、 甲苯 作用下， 生成 benzylsulfanyl-thioacetic acid amide
  参考文献：
  名称：

  Dahlbom, Acta Chemica Scandinavica (1947), 1952, vol. 6, p. 308

  摘要：

  DOI：
• 作为产物：
  描述：

  2-benzylthioacetyl chloride 在 氨 作用下， 以 苯 为溶剂， 反应 0.08h， 生成 alpha-(苄基硫代)乙酰胺
  参考文献：
  名称：

  Mori, Yuji; Fujiwara, Shigeru; Miyachi, Toshiko, Chemical and pharmaceutical bulletin, 1983, vol. 31, # 5, p. 1505 - 1517

  摘要：

  DOI：

文献信息

• [EN] NOVEL THIOPHENE AMIDINES, COMPOSITIONS THEREOF, AND METHODS OF TREATING COMPLEMENT-MEDIATED DISEASES AND CONDITIONS<br/>[FR] NOUVELLES AMIDINES DE THIOPHENE, COMPOSITIONS DE CES AMIDINES ET PROCEDE POUR TRAITER DES MALADIES ET DES ETATS MEDIES PAR LE COMPLEMENT
  申请人：DIMENSIONAL PHARM INC

  公开号：WO2003099805A1

  公开（公告）日：2003-12-04

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R1, R2, R3, R4 and R7 are defined in the specification, Z is SO or SO2, and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用化合物I的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本规范中定义的芳香族或杂环芳基。
• Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions
  申请人：3-Dimensional Pharmaceuticals, Inc.

  公开号：US20040009995A1

  公开（公告）日：2004-01-15

  Disclosed is a method for treating the symptoms of an acute or chronic disorder mediated by the classical pathway of the complement cascade, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I 1 or a solvate, hydrate or pharmaceutically acceptable salt thereof; wherein R 1 , R 2 , R 3 , R 4 and R 7 are defined in the specification, Z is SO or SO 2 , and Ar is an aromatic or heteroaromatic group as defined herein.

  揭示了一种治疗急性或慢性疾病症状的方法，该方法通过补体级联的经典途径介导，包括向需要此类治疗的哺乳动物施用公式I的化合物的治疗有效量或其溶剂化合物、水合物或药用可接受盐；其中在规范中定义了R1、R2、R3、R4和R7，Z为SO或SO2，Ar为本文中定义的芳香族或杂环芳基。
• POTENT AND SELECTIVE INHIBITORS OF NAV1.7
  申请人：AMGEN INC

  公开号：US20160024159A1

  公开（公告）日：2016-01-28

  Disclosed is a composition of matter comprising an isolated polypeptide, which is a peripherally-restricted Na V 1.7 inhibitor. In some disclosed embodiments, the isolated polypeptide is an inhibitor of Na V 1.7. Other embodiments are conjugated embodiments of the inventive composition of matter and pharmaceutical compositions containing the inventive composition of matter. Isolated nucleic acids encoding some embodiments of inventive polypeptides and expression vectors, and recombinant host cells containing them are disclosed. A method of treating or preventing pain is also disclosed.

  本文揭示了一种物质组合物，包括一种孤立的多肽，该多肽是一种外周限制的NaV1.7抑制剂。在一些公开的实施方式中，这种孤立的多肽是NaV1.7的抑制剂。其他实施方式是该物质组合物的共轭实施方式和含有该物质组合物的药物组合物。还揭示了编码一些创新多肽的孤立核酸和表达载体以及含有它们的重组宿主细胞。还揭示了一种治疗或预防疼痛的方法。
• Ruthenium-Catalysed Enantioselective Hydrogenation of Trisubstituted Enamides Derived from 2-Tetralone and 3-Chromanone: Influence of Substitution on the Amide Arm and the Aromatic Ring
  作者：J. L. Renaud、P. Dupau、A.-E. Hay、M. Guingouain、P. H. Dixneuf、C. Bruneau

  DOI：10.1002/adsc.200390017

  日期：2003.1

  Cyclic enamides were prepared in one step from tetralone and chromanone derivatives and primary amides under acidic conditions. The enantioselective hydrogenation of these enamides bearing an endocyclic trisubstituted carbon-carbon double bond was performed at room temperature in the presence of ruthenium catalysts. On the one hand, the nature of the amide group had little influence on the enantioselectivity

  在酸性条件下，由四氢萘酮和苯并二氢吡喃酮衍生物和伯酰胺一步制备环状酰胺。这些带有内环三取代碳-碳双键的酰胺的对映选择性氢化是在室温下在钌催化剂的存在下进行的。一方面，当使用单核预催化剂时，酰胺基的性质对氢化的对映选择性几乎没有影响。另一方面，在四氢萘酮和苯并二氢吡喃酮骨架上某些特定位置的配位原子的存在导致对映体过量的急剧减少。
• Pyrrole Derivatives As Pharmaceutical Agents
  申请人：Canne Bannen Lynne

  公开号：US20080234270A1

  公开（公告）日：2008-09-25

  Compounds, compositions and methods for modulating the activity of receptors are provided. In particular compounds and compositions are provided for modulating the activity of receptors and for the treatment, prevention, or amelioration of one or more symptoms of disease or disorder directly or indirectly related to the activity of the receptors.

  提供了用于调节受体活性的化合物、组合物和方法。特别提供了用于调节受体活性的化合物和组合物，以及用于治疗、预防或改善与受体活性直接或间接相关的一种或多种疾病或紊乱的症状的方法。